A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Butorphanol

Opioid Agonist/Antagonist class · 4 generic manufacturers · 9 ANDAs filed at FDA.

First FDA approval2002-03-12
Generic availableYes · 4 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$3.0M in CY2024 Part D spend36K claims · 5K beneficiaries · 329 plans surveyed

Lowest NADAC
$14.72/unit
2 NDCs benchmarked, lowest of all strengths.
Average NADAC
$14.72
Across all dosage forms in distribution.
Highest NADAC
$14.72
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Butorphanol used for?

Butorphanol is a Opioid Agonist/Antagonist medication tracked in Medicare Part D.

Is there a generic for Butorphanol?

Yes. 9 ANDAs filed at FDA, 4 generic manufacturers currently shipping.

How much does my plan pay for Butorphanol?

Across 329 Part D plans, Butorphanol averages $14.72/unit (NADAC). Lowest available: $14.72/unit. Highest in distribution: $14.72/unit.

Is Butorphanol on the FDA shortage list?

No. Butorphanol is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Opioid Agonist/Antagonist1 alternative in D1
01
Nalbuphine
Opioid Agonist/Antagonist
$4.32Lowest NADAC
2Generic mfrs
$532,092CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (9 approvals on file) · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.